未知生产厂商
scFv-h3D6 is a single-chain antibody fragment targeting the amyloid-β (Aβ) peptide, derived from the full-length antibody bapineuzumab. Designed by researchers at Universitat Autònoma de Barcelona (UAB), it lacks the Fc region to avoid recruiting systemic immune cells into the brain. Preclinical studies in the APP23 mouse model of Alzheimer's disease demonstrate that scFv-h3D6 avoids the cerebral haemorrhagic events caused by bapineuzumab while maintaining therapeutic efficacy.
scFv-h3D6 is a single-chain antibody fragment targeting the amyloid-β (Aβ) peptide, derived from the full-length antibody bapineuzumab. Designed by researchers at Universitat Autònoma de Barcelona (UAB), it lacks the Fc region to avoid recruiting systemic immune cells into the brain. Preclinical studies in the APP23 mouse model of Alzheimer's disease demonstrate that scFv-h3D6 avoids the cerebral haemorrhagic events caused by bapineuzumab while maintaining therapeutic efficacy.
scFv-h3D6 targets the amyloid-β (Aβ) peptide that accumulates in the brain of Alzheimer's disease patients. As a single-chain antibody fragment lacking the Fc region, it clears Aβ aggregates without recruiting systemic immune cells into the brain, thereby avoiding disruption of the blood-brain barrier and the associated cerebral haemorrhages that occur with full-length anti-Aβ antibodies.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
